Tetrahydrobiopterin

This MedLibrary.org supplementary page on Tetrahydrobiopterin is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Tetrahydrobiopterin
Systematic (IUPAC) name
(6R)-2-Amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(1H)-pteridinone
Identifiers
CAS number 17528-72-2
ATC code  ?
PubChem 44257
ChemSpider 1093
Chemical data
Formula C9H15N5O3 
Mol. mass 241.25
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Licence data

US

Pregnancy cat.

C(US)

Legal status

-only(US)

Routes Oral

Tetrahydrobiopterin, sapropterin, or BH4 is a naturally occurring essential cofactor of the three aromatic amino acid hydroxylases; phenylalanine-4-hydroxylase for conversion of phenylalanine to tyrosine, tyrosine-3-hydroxylase for the conversion of tyrosine to L-dopa, and tryptophan-5-hydroxylase for the conversion of tryptophan to 5-hydroxytryptophan. It is also essential for the synthesis of nitric oxide by nitric oxide synthase (NOS).

Contents

Clinical significance

A defect in BH4 synthesis and/or regeneration causes phenylketonuria type IV, as well as neurotransmitter (dopamine and serotonin) deficiency. Prolonged elevations in blood Phe levels in patients with PKU can result in severe neurologic damage, including severe mental retardation, microcephaly, delayed speech, seizures, and behavioral abnormalities.

Sapropterin, under the tradename Kuvan, is a synthetic preparation of the dihydrochloride salt of tetrahydrobiopterin.1 It was developed by BioMarin and approved by the US Food and Drug Administration on December 13, 2007. It is sold as tablets containing 100 mg. Sapropterin is the only drug approved for the treatment of phenylketonuria (PKU). Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

Synthesis

Tetrahydrobiopterin is synthesized from GTP by three enzymatic reactions (GTP cyclohydrolase I, 6-pyruvoyltetrahydropterin synthase, and sepiapterin reductase).2

History

Tetrahydrobiopterin has been discovered to play a role as biological cofactor by Seymour Kaufman. The first enzyme found to use tetrahydrobiopterin was phenylalanine hydroxylase. 3

See also

References

  1. ^ Barbara K. Burton, Santwana Kar & Peter Kirkpatrick (2008)). "Fresh from the Pipeline: Sapropterin". Nature Reviews Drug Discovery 7: 199–200. doi:10.1038/nrd2540. 
  2. ^ Thony B, Auerbach G, Blau N (2000). "Tetrahydrobiopterin biosynthesis, regeneration and functions". Biochem J 347 Pt 1: 1–16. doi:10.1042/0264-6021:3470001. PMID 10727395, http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=10727395. 
  3. ^ Kaufman, S (1958). "A New Cofactor Required for the Enzymatic Conversion of Phenylalanine to Tyrosine". J. Biol. Chem. (230): 931–39, http://www.jbc.org/cgi/reprint/230/2/931. 

External links

Wikipedia content modification information:

  • This page was last modified on 9 October 2008, at 00:46.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Tetrahydrobiopterin".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.